Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

32 results
Display

The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers

Hwang GY, Choi SY, Chang IH

To systematically review relevant literature on efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with advanced and metastatic urothelial cell cancer (UCC), renal cell cancer (RCC), and prostate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Experience of a Single Center in Treating Multiple Manifestations of Tuberous Sclerosis Complex with Everolimus

Ahn H, Yum MS, Jang HN, Song C, Ko TS

PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, for the treatment of tuberous sclerosis complex...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center

Kang SH, Hwang S, Ha TY, Song GW, Jung DH, Ahn CS, Moon DB, Kim KH, Park GC, Yoon YI, Park YH, Cho HD, Kwon JH, Chung YK, Choi JU, Lee SG

BACKGROUND: The mammalian target of the rapamycin inhibitor has dual inhibitory effects on cell growth and angiogenesis. This study aimed to analyze the usage of everolimus on actual immunosuppression (IS)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy

Lee SC, Kim KH, Kim OH, Lee SK, Hong HE, Choi BJ, Jeong W, Kim SJ

PURPOSE: Everolimus only inhibits mammalian target of rapamycin complex 1 (mTORC1), whereas Ku0063794 inhibits both mTORC1 and mTORC2. Although they have similar anticancer effects, their combination has a synergistic effect...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases

Alshahrani AA, Hwang S, Song GW, Moon DB, Jung DH, Ahn CS, Kim KH, Ha TY, Park GC, Ha SM, Park YH, Lee SG

Recurrence of hepatocellular carcinoma (HCC) 10 years after liver transplantation (LT) is very rare. Here, we present two cases of peritoneal metastasis of HCC that occurred 10 and 12 years...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of ⁶⁸Ga-DOTA-Peptide PET/CT on the Management of Gastrointestinal Neuroendocrine Tumour (GI-NET): Malaysian National Referral Centre Experience

Tan TH, Boey CY, Lee BN

PURPOSE: The National Cancer Institute is the only referral centre in Malaysia that provides ⁶⁸Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of ⁶⁸Ga-DOTA-peptide PET/CT on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus

Park SM, Kim BS, Kim MB, Lee YJ, Ko HC

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report

Cho CW, Lee N, Choi GS, Kim JM, Kwon CH, Joh JW

Clinical outcomes of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) in patients with multiple myeloma (MM) have not been established in terms of HCC recurrence and MM deterioration...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A cross-sectional analysis of long-term immunosuppressive regimens after liver transplantation at Asan Medical Center: Increased preference for mycophenolate mofetil

Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Lee SG

BACKGROUNDS/AIMS: Long-term immunosuppression regimens after liver transplantation (LT) are rarely reported in detail. We aimed to provide information on actual long-term immunosuppression regimens through this cross-sectional study. METHODS: Our institutional LT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tuberous Sclerosis Complex with Crohn's Disease

Kim MH, Lee YJ, Kim JY, Yi YY, Kang JW

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutation of one of two genes, TSC1 (encoding hamartin, 9q34) and TSC2 (encoding tuberin, 16p13). It invades the central...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma

Jeon SY, Yhim HY, Lee NR, Song EK, Kwak JY, Yim CY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

Yi Z, Ma F

Activation of the mammalian target of rapamycin (mTOR) signaling pathway is an important mechanism of resistance to endocrine therapy in breast cancer. Everolimus, an mTOR inhibitor, has been shown to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors

Thorat A, Jeng LB, Yang HR, Yeh CC, Hsu SC, Chen TH, Poon KS

BACKGROUNDS/AIMS: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Optimal Treatment of Advanced Pancreatic Neuroendocrine Tumor

Kim YS, Cho JH

Pancreatic neuroendocrine tumors (pNETs) are diverse diseases with different prognosis. Among available various therapeutic options, curative resection should be considered for localized tumors and in some selected cases of metastatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Heart Retransplantation to Treat a Case of Refractory Cardiac Allograft Vasculopathy

Lee SY, Choi JO, Kim YJ, Choi JS, Lee GY, Kim JS, Jeon ES

Cardiac allograft vasculopathy is one of the most important causes of poor long-term survival after heart transplantation. The condition tends to be diffuse, usually affecting the mid-to-distal portions of the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08

Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, Rha SY

PURPOSE: We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma

Kwon JH

Neuroendocrine carcinoma (NEC) has been reported to comprise 25% of lung cancer cases. NEC is classified as typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma, and small-cell lung cancer. Carcinoid tumors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Primary Lung Cancer Mistaken for Pulmonary Metastasis of Renal Cell Carcinoma

Kim JD, Kwon YJ, Lee ES, Kim YS, Lee YJ, Kong SM, Ji JH

Renal cell carcinoma (RCC) is rare relative to other urological cancers, but relatively common overall among males. Even when primary tumors are successfully removed by surgery, metastases are often noted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma

Kim LK, Ahn CH, Lee JE, Jung CH, Koo BK, Moon MK

  • KMID: 2269343
  • Korean J Med.
  • 2014 Jun;86(6):761-765.
Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr